CX Institutional Invests $294,000 in Edwards Lifesciences Co. (NYSE:EW)

CX Institutional bought a new position in shares of Edwards Lifesciences Co. (NYSE:EW) in the 4th quarter, HoldingsChannel reports. The institutional investor bought 3,968 shares of the medical research company’s stock, valued at approximately $294,000.

Other large investors have also made changes to their positions in the company. Bowman & Co S.C. increased its position in shares of Edwards Lifesciences by 1.2% during the fourth quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock worth $924,000 after purchasing an additional 148 shares in the last quarter. JFS Wealth Advisors LLC increased its position in shares of Edwards Lifesciences by 31.1% during the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after purchasing an additional 166 shares in the last quarter. Seascape Capital Management increased its position in shares of Edwards Lifesciences by 0.5% during the third quarter. Seascape Capital Management now owns 32,989 shares of the medical research company’s stock worth $2,177,000 after purchasing an additional 174 shares in the last quarter. Cooper Financial Group increased its position in shares of Edwards Lifesciences by 2.8% during the fourth quarter. Cooper Financial Group now owns 6,466 shares of the medical research company’s stock worth $479,000 after purchasing an additional 175 shares in the last quarter. Finally, Martin Capital Advisors LLP increased its position in shares of Edwards Lifesciences by 0.7% during the third quarter. Martin Capital Advisors LLP now owns 25,546 shares of the medical research company’s stock worth $1,686,000 after purchasing an additional 186 shares in the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Price Performance

EW opened at $68.98 on Monday. The stock’s 50-day moving average price is $72.33 and its 200 day moving average price is $70.52. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm has a market cap of $40.68 billion, a price-to-earnings ratio of 9.95, a PEG ratio of 3.54 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.67. The firm had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Edwards Lifesciences’s revenue was up 8.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.59 EPS. As a group, sell-side analysts expect that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on the company. The Goldman Sachs Group upped their target price on Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, December 5th. Sanford C. Bernstein upgraded Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. JPMorgan Chase & Co. upped their target price on Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a report on Friday, October 25th. Wolfe Research cut Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 target price for the company. in a report on Thursday, January 16th. Finally, Royal Bank of Canada upped their target price on Edwards Lifesciences from $80.00 to $85.00 and gave the company an “outperform” rating in a report on Thursday, December 5th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, Edwards Lifesciences presently has an average rating of “Hold” and an average target price of $78.48.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of the stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the sale, the vice president now owns 23,189 shares of the company’s stock, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Larry L. Wood sold 25,000 shares of the stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. This represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 33,000 shares of company stock valued at $2,195,180 in the last quarter. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.